Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Sant P. Chawla
Honoraria - Cytotech; Cytrex; GlaxoSmithKline; Johnson & Johnson; Merck; Sanofi ; SARC; Threshold
Research Funding - Cytotech; Cytrex; GlaxoSmithKline; Johnson & Johnson; Merck; Sanofi ; SARC; Threshold
Other Remuneration - Cytotech; Cytrex; GlaxoSmithKline; Johnson & Johnson; Merck; Sanofi ; SARC; Threshold
Isabelle Ray-Coquard
Honoraria - Amgen; Merck; Novartis; PharmaMar; Roche; Sanofi
Research Funding - Merck; Novartis; Roche
Axel Le Cesne
Honoraria - Novartis; Pfizer; PharmaMar
Arthur P. Staddon
Research Funding - ARIAD
Mohammed M. Milhem
No relevant relationships to disclose
Nicolas Penel
No relevant relationships to disclose
Richard F. Riedel
Consultant or Advisory Role - Merck
Research Funding - ARIAD
Binh Bui Nguyen
Consultant or Advisory Role - GlaxoSmithKline; Novartis; PharmaMar
Lee D. Cranmer
Honoraria - Merck
Research Funding - Merck
Peter Reichardt
Consultant or Advisory Role - MSD
Honoraria - MSD
Emmanuelle Bompas
No relevant relationships to disclose
Thierry Alcindor
Consultant or Advisory Role - Merck; Pfizer; Sanofi
Daniel A. Rushing
No relevant relationships to disclose
Yang Song
Employment or Leadership Position - Merck
Stock Ownership - Merck
Scot Ebbinghaus
Employment or Leadership Position - Merck
Stock Ownership - Merck
Frank G. Haluska
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Pierre F. Dodion
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
George D. Demetri
Consultant or Advisory Role - Amgen; ARIAD; ArQule; Daiichi Sankyo; GlaxoSmithKline; Infinity; Johnson & Johnson; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi ; ZIOPHARM Oncology
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Infinity; Johnson & Johnson; Novartis; Pfizer; Sanofi
Expert Testimony - ARIAD/Merck (U)